- Home
- ROIV vs VNO Comparison
ROIV vs VNO Comparison
Compare ROIV & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | VNO |
|---|---|---|
| Founded | 2014 | 1946 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 6.3B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | VNO |
|---|---|---|
| Price | $35.50 | $33.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $48.08 | $39.92 |
| AVG Volume (30 Days) | ★ 6.9M | 1.2M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | N/A | ★ 10400.00 |
| EPS | N/A | ★ N/A |
| Revenue | $8,260,000.00 | ★ $1,810,425,000.00 |
| Revenue This Year | $530.75 | $0.86 |
| Revenue Next Year | $685.92 | $6.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.27 |
| 52 Week Low | $15.25 | $24.57 |
| 52 Week High | $42.50 | $41.85 |
Technical Indicators
Market Signals| Indicator | ROIV | VNO |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 34.13 |
| Support Level | $33.15 | $32.67 |
| Resistance Level | $37.59 | $34.83 |
| Average True Range (ATR) | 1.21 | 0.92 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 22.31 | 1.74 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About VNO Vornado Realty Trust
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.